
## **Product Data Sheet**

## PE/Cy7 anti-human HLA-DR, DP, DQ

Catalog # / Size:	2408540 / 100 tests 2408535 / 25 tests	Γ
Clone:	Tü39	
Isotype:	Mouse IgG2a, к	rber
Immunogen:	Human PBL	elative Cell Number
<b>Reactivity:</b>	Human	
Preparation:	The antibody was purified by affinity chromatography and conjugated with PE/Cy7 under optimal conditions. The solution is free of unconjugated PE/Cy7 and unconjugated antibody.	Relat
Formulation:	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA).	Hun Iym
Concentration:	Lot-specific	puri Tü3



Human peripheral blood lymphocytes were stained with purified HLA-DR, DP, DQ (clone Tü39) PE/Cy7 (filled histogram) or mouse IgG2a, κ PE/Cy7 isotype control (open histogram).

## **Applications:**

Applications:	Flow Cytometry
Recommended Usage:	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes:	Tü39 has been reported to react with a shared epitope of HLA-DR, HLA-DP, and HLA-DQ.
	Additional reported applications (of relevant formats) include immunoprecipitation <sup>6</sup> , <i>in vitro</i> blocking of MLR5, and suppressor cell generation4. The LEAF <sup>™</sup> purified antibody (Endotoxin <0.1 EU/microg, Azide-Free, 0.2 μm filtered) is recommended for functional assays ( <u>contact our custom solutions</u> <u>team</u> ).
Application References:	<ol> <li>Pawelec G, <i>et al.</i> 1985. <i>Hum. Immunol.</i> 12:165.</li> <li>Shaw S, <i>et al.</i> 1985. <i>Hum. Immunol.</i> 12:191.</li> <li>Ziegler A, <i>et al.</i> 1986. <i>Immunobiology</i> 171:77.</li> <li>Pawelec G, <i>et al.</i> 1986. <i>Hum. Immunol.</i> 17:343. (Block)</li> <li>Dai Z, <i>et al.</i> 2009. <i>J. Exp. Med.</i> 206:793. (Block)</li> <li>Pawelec G, <i>et al.</i> 1988. <i>J. Exp. Med.</i> 167:243. (IP)</li> </ol>
Description:	HLA-DR, HLA-DP, and HLA-DQ are heterodimeric cell surface glycoproteins comprised of an $\alpha$ (heavy) chain and a $\beta$ (light) chain. They are expressed on B cells, activated T cells, monocytes/macrophages, dendritic cells, and other non-professional APCs. In conjunction with the CD3/TCR complex and CD4 molecules, HLA-DR is critical for efficient peptide presentation to CD4+ T cells. Variations in the HLA gene expression are crucial to graft survival.
Antigen	1. Thorsby E. 1974. <i>Transplant. Rev.</i> 18:51.

For research use only. Not for diagnostic use. Not for resale. Sony Biotechnology Inc. will not be held responsible for patent infringement or other violations that may occur with the use of our products. Sony Biotechnology Inc. 1730 North First Street, San Jose, CA 95112 www.sonybiotechnology.com

## 2. Qvigstad E, et al. 1984. Hum. Immunol. 11:207. **References:**

- Servenius B, *et al.* 1984. *EMBO J.* 3:3209.
   Ottenhoff TH, *et al.* 1985. *Hu*